What is myPath® Melanoma?
Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone.
The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30
90% - 94%
91% - 96%
Test Submission Process
How the myPath Melanoma Test Works
Covered by Medicare
9 out of 10 patients pay $0
The estimated average out-of-pocket cost
after insurance and financial assistance